Skip to main content

Table 3 Toxicities in Level-1 cohort

From: Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014

Toxicity

G1, %

G2, %

G3, %

G4, %

Hematologic

    

 Neutropenia

8

8

25

50

 Leukopenia

17

25

50

8

 Anemia

58

8

8

0

 Thrombocytopenia

25

8

0

0

Nonhematologic

    

 AST increased

17

0

0

0

 ALT increased

17

0

8

0

 Anorexia

25

42

8

0

 Nausea

42

8

8

0

 Diarrhea

17

17

8

0

 Vomiting

8

0

8

0

 Stomatitis

25

17

0

0

 Constipation

58

8

0

0

 Fatigue

42

8

0

0

 Hypertension

8

8

0

0

 Peripheral neuropathy

8

8

0

0

 Weight loss

17

0

0

0

 Arthralgia

8

0

0

0

 Febrile neutropenia

-

-

8

0

 Intracranial hemorrhage

0

0

8

0

  1. ALT: alanine aminotransferase, AST: aspartate aminotransferase, G: Grade (according to the National Cancer Institute’s Common Toxicity Criteria for Adverse Events, version 4.0)